Pemirolast K tablets 10 mg for allergy and asthma (Alegysal, Alamast)
Product Code :
Availability : 15
General information on Japanese Pemirolast K tablets 10 mg for allergy and asthma (Alegysal, Alamast)
Package details: 100 tablets
Manufacturer: Towa Pharmaceutical Co. Ltd., Japan
Active ingredient: pemirolast potassium (chemical formula C10H7KN6O)
Medical effect: Pemirolast K tablets are effective for the treatment of bronchial asthma and allergic rhinitis.
Contraindications and precautions: do not use in pregnant or breastfeeding women.
If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Pemirolast K tablets 10 mg from Japan for allergy and asthma
- For bronchial asthma in adults and children 11 years old or above: take 1 tablet at a time, 2 times a day after meal.
- For bronchial asthma in children between 5 and 10 years old: take 0.5 tablet at a time, 2 times a day after meal.
- For bronchial asthma in children under 5 years old: do not use.
- For allergic rhinitis in adults: take 0.5 tablet at a time, 2 times a day, after meal.
The dosage may be adjusted by the consulting doctor according to the disease, age and symptoms.
How effective are Japanese Pemirolast K tablets 10 mg for allergy and asthma?
Pemirolast potassium is a mast cell stabilizer that acts as an antiallergic agent. It works by binding to the histamine H1 receptor and blocking the action of endogenous histamine. Also, Pemirolast tablets inhibit the antigen-induced release of inflammatory mediators like histamine, leukotriene C4, D4, E4 from human mast cells. As the result, they effectively prevent the occurrence of allergy symptoms.
Who should take Pemirolast K tablets 10 mg from Japan?
Pemirolast tablets effectively prevent acute manifestations of allergic rhinitis and bronchial asthma. However, this medicine is not designed to immediately reduce attacks or symptoms that have already started. Studies showed the Pemirolast does not have side effects, significantly reduce nocturnal symptoms and bronchodilator use in patients with asthma and improve sneezing, rhinorrhea, and stuffy nose in patients with seasonal allergic rhinitis (D. G. Tinkelman, R. B. Berkowitz. "A pilot study of pemirolast in patients with seasonal allergic rhinitis". Ann Allergy. 1991, February, 66 (2): 162-165; J. P. Kemp, I. L. Bernstein et al. “Pemirolast, a new oral nonbronchodilator drug for chronic asthma”. Ann Allergy. 1992, June, 68(6): 488-491).